Report: Abiomed claims Impella pump not at fault in patient death

After reporting issues with two of its Impella heart pumps used in a failed surgery, Abiomed (NSDQ:ABMD) said today that the devices were not to blame for the patient’s death, according to a Boston Business Journal report.

Abiomed reported issues with two Impella pumps in a posting to the federal watchdog’s Medsun database last month.

The issues were investigated by engineers, who found material in the first pump that reduced flow and that the pump housing/outlet cage cage and impeller were crushed in the second Impella device, according to the posting.

Abiomed CEO Mike Minogue said that a blood clot had been detected in the first pump, which triggered a safety mechanism to stop the pump from pushing the clot into the patients’ brain, while the second pump was bent during the insertion process, according to the BBJ report.

“We’re saddened to hear of any patient’s death from heart disease, and this only increases our commitment to our mission of recovering hearts and saving lives. We closely track our cases, reviewed this case when it happened, and it was determined Impella was not related to the outcome,” CEO Minogue said in a statement, according to the report.

Last month, Abiomed joined a $7 million financing round for RenalGuard Solutions.

The post Report: Abiomed claims Impella pump not at fault in patient death appeared first on MassDevice.

from MassDevice https://ift.tt/2Ccyb2b